Sunday, 20 September 2026European Markets

FINATIS Stock Rises By 21% In The Last 10 Sessions

Loading stream...

(vianews) - shares of finatis (cac 40: fnts.pa) jumped by a staggering 21.95% in 10 sessions from €4.1 to €5.00 at 08:53 est on friday, after five sequential sessions in a row of losses. cac 40 is rising 0.36% to €7,312.73, after four successive sessions in a row of gains.

about finatis

finatis société anonyme operates in the food distribution business in france and latin america. it operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. the company also distributes sports equipment under the go sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. the company was incorporated in 1971 and is headquartered in paris, france. finatis société anonyme is a subsidiary of euris sas.

earnings per share

as for profitability, finatis has a trailing twelve months eps of €-29.96.

volume

today's last reported volume for finatis is 20 which is 86.5% below its average volume of 163.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com